← All trials
NCT02624349
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2013
- Primary completion
- Apr 1, 2016
- Completion date
- May 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 130
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of TorontoLead sponsor
- MerckCollaborator
- University of TorontoOverall official - principal investigator
- University of TorontoReponsible party - principal investigator
- The Physicians' Services Incorporated FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.